Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (204 reviews)

For research use only.

Catalog No.S1011

204 publications

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

Selleck's Afatinib (BIBW2992) has been cited by 204 publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cell Death Dis, 2020, 2;11(1):6

PubMed: 31919341 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )
Antimicrob Agents Chemother, 2020, 1;AAC.00341-20

PubMed: 32482675 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):847-856 eCollection 2020

PubMed: 32269717 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Korean J Parasitol, 2020, 58(3):249-255

PubMed: 32615738 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

J Cancer, 2020, 11(1):241-250

PubMed: 31892990 ( click the link to review the publication )

Neurooncol Adv, 2020, Dec;2(1):vdaa020

PubMed: 32226941 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )
Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )
J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9):e8746

PubMed: 30021798 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )
Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )
Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )
Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )
Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	NGPDfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3yXVhKSzVyPUCuNFA2PzJizszN	M4HXSnNCVkeHUh?=
KASUMI-1	NH;mTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\IRmlEPTB;MD6wNFkyOSEQvF2=	MmrEV2FPT0WU
HCC2218	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rnXWlEPTB;MD6wNFk5PyEQvF2=	NILFOotUSU6JRWK=
KARPAS-45	NFLs[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LjfGlEPTB;MD6wNVY4OSEQvF2=	MmPqV2FPT0WU
HSC-4	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGj6VYZKSzVyPUCuNFE4PDhizszN	M1HxZXNCVkeHUh?=
CHL-1	NYDIPJFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEG4N\|kh\|ryP	NXfXdHFYW0GQR1XS
KY821	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYixUZZ6UUN3ME2wMlAzODZizszN	M3zKNXNCVkeHUh?=
NCI-N87	NH3hSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq3fnFVUUN3ME2wMlAzPzd\|IN88US=>	NXPKV5BPW0GQR1XS
DOK	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\COmlEPTB;MD6wN\|E6PCEQvF2=	NV3uZ3FvW0GQR1XS
DSH1	MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEOzNVQh\|ryP	M2DNbnNCVkeHUh?=
MDA-MB-175-VII	MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMEO0NVYh\|ryP	NWi0SpNVW0GQR1XS
NCI-H2170	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEj6emVKSzVyPUCuNFM4OjhizszN	NEHoRpNUSU6JRWK=
BT-474	NEG1NJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMES5PFYh\|ryP	MVXTRW5ITVJ?
EFO-27	NH;0fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\Cd2lEPTB;MD6wOVE5OiEQvF2=	M2Txd3NCVkeHUh?=
NCI-H720	M2Xme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr4W203UUN3ME2wMlA2OzJ3IN88US=>	NGXlRoZUSU6JRWK=
PC-14	NF;u[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLHUZZKSzVyPUCuNFU3PjhizszN	NYezdYxxW0GQR1XS
EC-GI-10	NGnZXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjiemFKSzVyPUCuNFU6OTJizszN	NYjiUnVxW0GQR1XS
KYSE-450	M12xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfVWWZXUUN3ME2wMlA2QTd6IN88US=>	NWj2TpJIW0GQR1XS
BPH-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\NSHRkUUN3ME2wMlA2QTh6IN88US=>	NYqxdIxCW0GQR1XS
NCI-H292	M1f5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwME[wPUDPxE1?	MnH5V2FPT0WU
H9	NFrqeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTsOppKSzVyPUCuNFcyOzJizszN	NGHuWplUSU6JRWK=
NCI-H526	M3XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLmPGlKSzVyPUCuNFc5OjNizszN	MXHTRW5ITVJ?
NCI-H1623	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPaW5JVUUN3ME2wMlA5ODJ3IN88US=>	NF36c3lUSU6JRWK=
KYSE-140	Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMEizN{DPxE1?	M2DVd3NCVkeHUh?=
Ca9-22	M1;tZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\h[FlKSzVyPUCuNFg{PTNizszN	MoPoV2FPT0WU
AU565	NWfod4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInucZRKSzVyPUCuNFg2ODRizszN	Mmr4V2FPT0WU
ZR-75-30	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPqRm1KSzVyPUCuNFk2PDVizszN	MUPTRW5ITVJ?
NCI-H1770	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzCTWM2OD1yLkGwNlgh\|ryP	NFjUWIJUSU6JRWK=
LB2241-RCC	M2nrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMUC4PFQh\|ryP	MofrV2FPT0WU
CAL-39	MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLnN49wUUN3ME2wMlEyPzl{IN88US=>	NHP0dG9USU6JRWK=
UACC-893	M{OyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXvXpp[UUN3ME2wMlEyQDh3IN88US=>	MmrIV2FPT0WU
LU-65	M1LXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3i3dmlEPTB;MD6xNlY{OyEQvF2=	MYPTRW5ITVJ?
HN	NH3qeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInSXYFKSzVyPUCuNVMxPzdizszN	NGHyNoVUSU6JRWK=
TI-73	NF\SW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;MT2lEPTB;MD6xOFcyPSEQvF2=	M{LIUHNCVkeHUh?=
KU812	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3xU2xKSzVyPUCuNVU1PTZizszN	NFLJSmlUSU6JRWK=
SW13	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEKxeGJKSzVyPUCuNVYzOTZizszN	NHTqUZJUSU6JRWK=
BB30-HNC	M{\tXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMU[1O\|Yh\|ryP	MXPTRW5ITVJ?
HSC-2	NWfVZZBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TFV2lEPTB;MD6xOlg{PyEQvF2=	MYPTRW5ITVJ?
BV-173	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HUN2lEPTB;MD6xO\|U6PiEQvF2=	NFHpS2lUSU6JRWK=
CAL-27	M2rrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLtNoRKSzVyPUCuNVc3OzZizszN	MnT3V2FPT0WU
SBC-1	M4PBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfKZWVKSzVyPUCuNVg6PTlizszN	M{\0b3NCVkeHUh?=
CAL-33	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjHOVF7UUN3ME2wMlIxOTh2IN88US=>	M2jkWXNCVkeHUh?=
NCI-H209	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnrVY9zUUN3ME2wMlIxPDZizszN	Mn\qV2FPT0WU
COR-L105	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj2UYpWUUN3ME2wMlIyODh2IN88US=>	NXuwb2JNW0GQR1XS
HSC-3	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMkGxPVgh\|ryP	MnjpV2FPT0WU
NCI-H69	NUPlfYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4H6ZWlEPTB;MD6yNVQ2OSEQvF2=	M2LyUXNCVkeHUh?=
MOLT-13	NHXH[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXyTWM2OD1yLkKzPVc2KM7:TR?=	NUnidFB[W0GQR1XS
ML-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrDZ29KSzVyPUCuNlQ5ODJizszN	NGjiUo5USU6JRWK=
IGROV-1	NH\2N2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\xTWM2OD1yLkK1PVUzKM7:TR?=	NYTTXXo4W0GQR1XS
TK10	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE[wRnZKSzVyPUCuNlY4OzhizszN	MV3TRW5ITVJ?
EoL-1-cell	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f5XGlEPTB;MD6yOlg6OiEQvF2=	M4HNZnNCVkeHUh?=
HO-1-N-1	NU\CdmF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjocYhrUUN3ME2wMlI4QDV\|IN88US=>	M3mw[3NCVkeHUh?=
BHY	NVHOUHp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMki2OVUh\|ryP	MV;TRW5ITVJ?
LU-139	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LuWmlEPTB;MD6zNFUyKM7:TR?=	NIHJdI9USU6JRWK=
23132-87	NY\NPHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELYdnpKSzVyPUCuN\|E6OjNizszN	MVXTRW5ITVJ?
ACHN	NFXFbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jhNGlEPTB;MD6zNVk6PCEQvF2=	NULs[\|BuW0GQR1XS
DoTc2-4510	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLzTWM2OD1yLkOyNlE6KM7:TR?=	MVTTRW5ITVJ?
BB65-RCC	M2XiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfseo5sUUN3ME2wMlM1PTl\|IN88US=>	MknYV2FPT0WU
HLE	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkSyTWM2OD1yLkO1NFQ3KM7:TR?=	NHO3XY1USU6JRWK=
HCC1419	NHzhXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrFdYVKSzVyPUCuN\|Y1ODhizszN	Mn7iV2FPT0WU
A388	NWP0TmdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3W3dmlEPTB;MD6zOlg2PyEQvF2=	M1XMV3NCVkeHUh?=
NUGC-3	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TS[mlEPTB;MD6zPFM4OyEQvF2=	NFv4V2NUSU6JRWK=
KYSE-180	NXjlOJN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwM{mwPFkh\|ryP	M1nzUHNCVkeHUh?=
TE-6	MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjvTVdKSzVyPUCuOFAzPDZizszN	MVHTRW5ITVJ?
A498	M2KxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwNEC2O\|Qh\|ryP	NHfKdldUSU6JRWK=
NCI-H1648	M3T5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXzTWM2OD1yLkS0NVgzKM7:TR?=	NFPDR\|FUSU6JRWK=
DU-145	NGHRXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4i0UWlEPTB;MD60OFg{OyEQvF2=	M160PHNCVkeHUh?=
CW-2	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwNE[5NVQh\|ryP	NWTiTmdKW0GQR1XS
A431	M3nremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrje5BIUUN3ME2wMlQ5OjN\|IN88US=>	NGXMeXdUSU6JRWK=
SAS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnVe2FWUUN3ME2wMlQ5Ozl6IN88US=>	M{HrSXNCVkeHUh?=
NCI-H2126	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwNUG5NlYh\|ryP	Mlr5V2FPT0WU
NCI-H358	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwNUOyNUDPxE1?	NGfrWlRUSU6JRWK=
FADU	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fGXmlEPTB;MD61OFQxPCEQvF2=	NHvCPGZUSU6JRWK=
ACN	NVeyOYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XZOmlEPTB;MD61OVA6PCEQvF2=	NWK2O\|I4W0GQR1XS
HCC70	NHH2UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmr2TWM2OD1yLkW3OlYyKM7:TR?=	M1n0UHNCVkeHUh?=
NCI-H1838	NFTEVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwNkCyPVkh\|ryP	MXjTRW5ITVJ?
CAL-54	M{jVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTwRlNxUUN3ME2wMlYyPjJzIN88US=>	MWfTRW5ITVJ?
NCI-H1975	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4j3O2lEPTB;MD62NVczQCEQvF2=	NHLtXppUSU6JRWK=
COR-L88	M2f0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwNkSxNVMh\|ryP	M{LKSXNCVkeHUh?=
CTV-1	M4HPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFG0TJNKSzVyPUCuOlQ{QTJizszN	MlzaV2FPT0WU
EW-18	MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH5SotKSzVyPUCuOlg3QThizszN	M1zaXHNCVkeHUh?=
HCC1806	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNkm2OlYh\|ryP	NH;TSHhUSU6JRWK=
HuP-T4	NXXjUmduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDFbmx2UUN3ME2wMlY6PzZizszN	M{DmT3NCVkeHUh?=
MDA-MB-361	NIe3fZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlz0TWM2OD1yLkeyOlYzKM7:TR?=	NUPFd2NsW0GQR1XS
NCI-H1573	NECyRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1W5[GlEPTB;MD63N\|Y{KM7:TR?=	NVPK[406W0GQR1XS
KU-19-19	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnWxTWM2OD1yLke3OFY1KM7:TR?=	Mn62V2FPT0WU
COLO-678	NH7pOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwOEC4N\|Qh\|ryP	MYfTRW5ITVJ?
C-33-A	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjaVJI5UUN3ME2wMlgyOjl5IN88US=>	M4HhV3NCVkeHUh?=
Calu-3	NXPGc5c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LVXGlEPTB;MD64NVQ{PCEQvF2=	NXPMXFBEW0GQR1XS
AGS	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\NTWM2OD1yLkizOlQ5KM7:TR?=	NGHoRpRUSU6JRWK=
SCC-25	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\DTWM2OD1yLki0NVcyKM7:TR?=	MXjTRW5ITVJ?
JVM-2	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlj3TWM2OD1yLki4Nlk6KM7:TR?=	M4fGRXNCVkeHUh?=
HCE-T	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjkNmJUUUN3ME2wMlg5PDJ6IN88US=>	NFm0XWRUSU6JRWK=
ES4	NHjIe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwOUe4N\|Yh\|ryP	M3zV[HNCVkeHUh?=
EKVX	NXHNPG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nBeWlEPTB;MT6wNVA3PCEQvF2=	MUfTRW5ITVJ?
D-542MG	M17pZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFwMEGwOlQh\|ryP	MXLTRW5ITVJ?
SW1116	NVvmc\|RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7vNGZGUUN3ME2xMlAyOjh5IN88US=>	NEPJ[mhUSU6JRWK=
5637	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvSNmg2UUN3ME2xMlAyPTFizszN	MorWV2FPT0WU
HT-1376	NV:ydINpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XsTmlEPTB;MT6wNVUyOyEQvF2=	NI\qeHZUSU6JRWK=
NB69	NGCzfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zJXmlEPTB;MT6wNlk1PSEQvF2=	NHn0[JBUSU6JRWK=
YKG-1	NGfON\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;yTWM2OD1zLkC1OFE6KM7:TR?=	NVrSfIt1W0GQR1XS
EW-3	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXN[5ZKSzVyPUGuNFc5QDNizszN	MWnTRW5ITVJ?
GCIY	NIPU[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nXeGlEPTB;MT6wPFExPCEQvF2=	MnuyV2FPT0WU
SK-MES-1	NF:2Z5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jwPWlEPTB;MT6xNVQ5PyEQvF2=	M4ThVHNCVkeHUh?=
PANC-08-13	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;P[IpKSzVyPUGuNVY1OTZizszN	MXTTRW5ITVJ?
SK-NEP-1	M1TSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXiTWM2OD1zLkG3OVE{KM7:TR?=	NInUXWRUSU6JRWK=
SW954	NVnqWJBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLWWYJmUUN3ME2xMlIxOjF2IN88US=>	NWLHSYlFW0GQR1XS
NCI-SNU-5	M2LUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFwMkO5JO69VQ>?	NYL0VJcyW0GQR1XS
SW48	M3m5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzkb5NRUUN3ME2xMlI2PDN{IN88US=>	M3m4bHNCVkeHUh?=
HT-3	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLRepdVUUN3ME2xMlI5PzV\|IN88US=>	MYLTRW5ITVJ?
ETK-1	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnKTWM2OD1zLkO3OFU3KM7:TR?=	MV3TRW5ITVJ?
SCC-15	NF36UJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX71N3lUUUN3ME2xMlM6PDVzIN88US=>	M4j5cHNCVkeHUh?=
DU-4475	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPDPHh5UUN3ME2xMlQxOTJzIN88US=>	NHW5fIdUSU6JRWK=
NB5	M3G1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWq4TlhLUUN3ME2xMlQyOzF5IN88US=>	M3nDZXNCVkeHUh?=
CFPAC-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPidVlMUUN3ME2xMlQzPDl\|IN88US=>	NXjqSJl3W0GQR1XS
NCI-H630	NID5VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFwNEW1PFIh\|ryP	NGjp[GhUSU6JRWK=
NCI-H82	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvOTWM2OD1zLkW0NFA3KM7:TR?=	MlHMV2FPT0WU
ECC10	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfj[ZhKSzVyPUGuOVU{PjlizszN	M2DE[nNCVkeHUh?=
K5	NGTBW2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXBSI82UUN3ME2xMlU5OzV5IN88US=>	NVzlPJp6W0GQR1XS
ME-180	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTUNY9KSzVyPUGuOlExQTZizszN	NETNR4JUSU6JRWK=
KYSE-410	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfaTWM2OD1zLk[1OlczKM7:TR?=	M4LoZnNCVkeHUh?=
G-401	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrXTWM2OD1zLk[3OFE{KM7:TR?=	MVXTRW5ITVJ?
TGBC24TKB	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnqV2VoUUN3ME2xMlY5OjNizszN	MknFV2FPT0WU
Detroit562	M4Dse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPa[\|dKSzVyPUGuO\|AyPTJizszN	Mmr6V2FPT0WU
OE19	MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTFwN{G1NVIh\|ryP	MYfTRW5ITVJ?
CAKI-1	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTFwN{iyNVEh\|ryP	MWDTRW5ITVJ?
TE-12	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwOEC0NVQh\|ryP	M4LNbnNCVkeHUh?=
NCI-H1666	NH7jT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\pWGlEPTB;MT64NFk1QCEQvF2=	M4mwZXNCVkeHUh?=
TE-1	M{DoSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTFwOEG0O\|Uh\|ryP	NUe1Z45TW0GQR1XS
CAL-12T	M33Pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjtfJB2UUN3ME2xMlg5QTR3IN88US=>	MWDTRW5ITVJ?
TE-8	M3i1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrkOppKSzVyPUGuPVE{PzdizszN	NIXYO3BUSU6JRWK=
KYSE-270	NUe4eXQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPtTWM2OD1{LkCyO\|MzKM7:TR?=	NUnlVGNQW0GQR1XS
GMS-10	M2XOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFGwWlZKSzVyPUKuNFM2OTdizszN	NE\3VnVUSU6JRWK=
A2780	MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfQZYRkUUN3ME2yMlA3Ojl2IN88US=>	MX\TRW5ITVJ?
OMC-1	M3j3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXrXphzUUN3ME2yMlA5OTZ7IN88US=>	NI\B[INUSU6JRWK=
LoVo	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvXTWM2OD1{LkGwO\|k4KM7:TR?=	NWS4VlV[W0GQR1XS
PANC-03-27	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3ETWM2OD1{LkG2OlMyKM7:TR?=	MUHTRW5ITVJ?
MDA-MB-157	NWfxNnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\4OWlEPTB;Mj6yNVgzQCEQvF2=	MYTTRW5ITVJ?
CaR-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TpdWlEPTB;Mj6yPFI5OSEQvF2=	MnLTV2FPT0WU
769-P	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HUUmlEPTB;Mj6yPVA{PyEQvF2=	NU\k[ZlVW0GQR1XS
NB7	NGjWcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[5OGlEPTB;Mj6yPVY4PiEQvF2=	NYXjS4g6W0GQR1XS
MKN7	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTxR25KSzVyPUKuN\|U{OzVizszN	MWHTRW5ITVJ?
NCI-H1048	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTJwNEmxOVgh\|ryP	MlPQV2FPT0WU
RCM-1	NVLEPJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M36w[GlEPTB;Mj61Nlk{QCEQvF2=	NHvkO\|RUSU6JRWK=
HT55	NXvud3dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGniWXFKSzVyPUKuOVc{QCEQvF2=	M4XlOHNCVkeHUh?=
HCC1569	NV;odXZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDST2pDUUN3ME2yMlU5Ojl5IN88US=>	NXTYclVjW0GQR1XS
LXF-289	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfsc3JKSzVyPUKuOlM2PjVizszN	M1TaenNCVkeHUh?=
OVCAR-3	MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jsbmlEPTB;Mj62O\|E3PyEQvF2=	NV;YOldvW0GQR1XS
TE-10	NV3sV2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\DVWlEPTB;Mj62PFA4QCEQvF2=	MojBV2FPT0WU
SNU-C2B	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjocmhKSzVyPUKuOlg3OTZizszN	M{PTN3NCVkeHUh?=
LB1047-RCC	NIn6fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXTZWljUUN3ME2yMlc1QDh6IN88US=>	M{jpOnNCVkeHUh?=
SN12C	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJwOUG5OlQh\|ryP	NH;re\|FUSU6JRWK=
786-0	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTNwME[0NFgh\|ryP	MkPUV2FPT0WU
HT-29	NHzES2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzWWnp2UUN3ME2zMlA4OzB7IN88US=>	NH\iWGtUSU6JRWK=
RPMI-7951	M1rydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTNwMEe1PUDPxE1?	MUnTRW5ITVJ?
NBsusSR	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrQTIM5UUN3ME2zMlE5OjV2IN88US=>	NYnpe3p[W0GQR1XS
NKM-1	M4rxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTNwMUi3OFQh\|ryP	NGf0b5BUSU6JRWK=
Capan-2	M3H2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkX4TWM2OD1\|LkS2PFc2KM7:TR?=	M{jjZ3NCVkeHUh?=
MKN1	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIKzSJFKSzVyPUOuOFcyODhizszN	NETGfY5USU6JRWK=
OAW-42	M1vZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvtNXZKSzVyPUOuOVAxOjZizszN	M{S5SnNCVkeHUh?=
SKG-IIIa	MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1npNGlEPTB;Mz61NlI{PyEQvF2=	MX\TRW5ITVJ?
no-11	NF;GcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTNwNUO1OlQh\|ryP	Ml:3V2FPT0WU
NY	M1vsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTNwNUO2OVUh\|ryP	NHPRcItUSU6JRWK=
HEC-1	M4j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTNwNUi5OUDPxE1?	NXTSZm4{W0GQR1XS
NCI-H441	NFvTdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHRfGl2UUN3ME2zMlU6QDRzIN88US=>	Mmq2V2FPT0WU
NCI-H2009	NEDxfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrqTWM2OD1\|Lk[xNlE3KM7:TR?=	NWWzWJM2W0GQR1XS
T47D	M133Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PZ[2lEPTB;Mz62NlIyPyEQvF2=	MnvKV2FPT0WU
SNU-449	NV3VZVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHzVHNXUUN3ME2zMlY2QDJ4IN88US=>	M2nNbXNCVkeHUh?=
NCI-SNU-1	M2r3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLOWJZKSzVyPUOuOlk4OzVizszN	NILxPI5USU6JRWK=
BT-20	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUeyUHRlUUN3ME2zMlY6Pzl3IN88US=>	NVnYcnBvW0GQR1XS
LS-123	M4n3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1y3U2lEPTB;Mz63OFI5PCEQvF2=	M{XwbHNCVkeHUh?=
8305C	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGC3TVBKSzVyPUOuO\|U6OTFizszN	MXjTRW5ITVJ?
OCUB-M	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\6TWM2OD1\|Lke2NVg4KM7:TR?=	MUfTRW5ITVJ?
KOSC-2	M3LZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoX3TWM2OD1\|LkizOFUyKM7:TR?=	MkXOV2FPT0WU
NCI-H1693	NXiwR3YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTNwOESxPFEh\|ryP	M17RenNCVkeHUh?=
TE-9	M1nVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTNwOESzPFIh\|ryP	NVrjdHVSW0GQR1XS
MV-4-11	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTNwOEe5PVQh\|ryP	NVPqb4syW0GQR1XS
GAMG	NVraW3htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnaTWM2OD1\|LkmxN\|E1KM7:TR?=	NHjRb\|BUSU6JRWK=
KNS-62	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Dl[2lEPTB;Mz65OFc{OSEQvF2=	MYPTRW5ITVJ?
MC116	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XtXGlEPTB;Mz65OVQ5QSEQvF2=	M3nhUXNCVkeHUh?=
647-V	M17ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLhUYRKSzVyPUOuPVg1PTJizszN	NXWxTotrW0GQR1XS
U-87-MG	NHHSNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjyTWM2OD12LkGwOFgyKM7:TR?=	MWTTRW5ITVJ?
RPMI-8226	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\jd2lEPTB;ND6xNVY{OSEQvF2=	MYTTRW5ITVJ?
SW1417	NVzIUmFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;DUVdKSzVyPUSuNVIyPDdizszN	M2rDTnNCVkeHUh?=
LAMA-84	NH;Mbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnK0TWM2OD12LkG3NFIh\|ryP	MlzXV2FPT0WU
LS-513	M4K5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fZeWlEPTB;ND6zNVIyPyEQvF2=	MkH3V2FPT0WU
KLE	M4ThS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1K4dmlEPTB;ND60NFgyQSEQvF2=	NYjBN4RyW0GQR1XS
HCT-116	M1juPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHITWM2OD12LkSxNFA4KM7:TR?=	M{nkXnNCVkeHUh?=
EPLC-272H	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDMd49KSzVyPUSuOFE2OzNizszN	MXHTRW5ITVJ?
KS-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nhe2lEPTB;ND61NFg5QSEQvF2=	NFTYOWFUSU6JRWK=
HT-1197	NYLCPG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D5fWlEPTB;ND61NlY3QSEQvF2=	NYTrXYhVW0GQR1XS
LCLC-97TM1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTUT2o3UUN3ME20MlU{Pjh4IN88US=>	M1\Gd3NCVkeHUh?=
ES5	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TJO2lEPTB;ND64N\|czOyEQvF2=	NIXLd25USU6JRWK=
CTB-1	NV:wcGk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlL5TWM2OD12Lki0PFgh\|ryP	NFm0NpBUSU6JRWK=
HL-60	M2H4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;ub2lEPTB;ND64OlYyOSEQvF2=	Mo\yV2FPT0WU
VM-CUB-1	NVnjRVBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3uzNWlEPTB;ND64OlgyQSEQvF2=	MknvV2FPT0WU
MEG-01	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTRwOUm0NFMh\|ryP	MlSwV2FPT0WU
KYSE-520	NXrIW3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULxbXRlUUN3ME21MlIxQDN7IN88US=>	MV;TRW5ITVJ?
HuO-3N1	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLGTWM2OD13LkK0NFQ{KM7:TR?=	NF\3cYNUSU6JRWK=
SW620	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTVwMkS5OlQh\|ryP	NF\pOm9USU6JRWK=
U031	NXTQOnBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXOTWM2OD13LkK1OFI1KM7:TR?=	MlzMV2FPT0WU
TE-5	M2HSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH24d4JKSzVyPUWuOFA5PSEQvF2=	NWjLbWkzW0GQR1XS
NCI-H747	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzqTJhKSzVyPUWuOFI1PzJizszN	NGXwS3hUSU6JRWK=
MG-63	MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTVwNEi3OlIh\|ryP	M321cXNCVkeHUh?=
HC-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTwTWM2OD13LkWxPFM6KM7:TR?=	NWfL[npLW0GQR1XS
HCC2998	NEnVNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjRbGRiUUN3ME21MlUzPjF3IN88US=>	MVHTRW5ITVJ?
NTERA-S-cl-D1	NGjMfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XJVGlEPTB;NT61OFU{PyEQvF2=	NWLyR4JPW0GQR1XS
KINGS-1	M2LlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LmcmlEPTB;NT62NFk1PCEQvF2=	Mk\RV2FPT0WU
D-423MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPhTWM2OD13Lk[xO\|A2KM7:TR?=	MULTRW5ITVJ?
SW962	NXqx[GsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fZN2lEPTB;NT62NlA{OiEQvF2=	M3THZnNCVkeHUh?=
LOXIMVI	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTVwNkO4O\|Mh\|ryP	NGjSeWVUSU6JRWK=
LS-411N	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIG0S\|NKSzVyPUWuO\|k1PDFizszN	MoO0V2FPT0WU
NCI-H2291	NHzMSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLlZpA5UUN3ME21Mlk5QTR\|IN88US=>	MYrTRW5ITVJ?
A549	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfrdJZNUUN3ME22MlEzPTV\|IN88US=>	M3;zWXNCVkeHUh?=
LS-1034	NEjzcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\rdoJUUUN3ME22MlIxPzB4IN88US=>	NHnWbWdUSU6JRWK=
NB14	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HtSWlEPTB;Nj60N\|g{PiEQvF2=	MnvEV2FPT0WU
NCI-H1299	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3FZVNKSzVyPU[uOlMyPzFizszN	MVTTRW5ITVJ?
BT-549	M4j4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTZwNk[4PFkh\|ryP	MXzTRW5ITVJ?
J-RT3-T3-5	NIjsZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fTb2lEPTB;Nj64Olkh\|ryP	M4HOO3NCVkeHUh?=
SW756	NXvQO\|I6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrlUo1KSzVyPU[uPVEyPzZizszN	M2DO[XNCVkeHUh?=
DJM-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTZwOUKwNVIh\|ryP	NFnJNZRUSU6JRWK=
GP5d	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPXVXl2UUN3ME22Mlk4Ozl2IN88US=>	NVS5UWpIW0GQR1XS
MOLT-4	M{PGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHaTWM2OD15LkCyNVM2KM7:TR?=	NYTnNpZNW0GQR1XS
NCI-H28	M1zwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHTTWM2OD15LkG2OFA2KM7:TR?=	MUjTRW5ITVJ?
MN-60	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXYOHUzUUN3ME23MlI5ODh7IN88US=>	M4j3SnNCVkeHUh?=
RMG-I	NFn0cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTdwM{myPVYh\|ryP	MlnnV2FPT0WU
COLO-800	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTdwNEG0OFYh\|ryP	M4HifnNCVkeHUh?=
DB	NHT1OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXITZB2UUN3ME23MlYyODB3IN88US=>	M1PrSHNCVkeHUh?=
Ca-Ski	M1vz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HzS2lEPTB;Nz62OFI2QSEQvF2=	NXXaO\|I4W0GQR1XS
HEL	NYCzTno5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjYeWVKSzVyPUeuO\|EzODNizszN	MX3TRW5ITVJ?
NH-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPiO4JKSzVyPUeuO\|I5ODhizszN	NXLyWnNxW0GQR1XS
LB373-MEL-D	NFPUOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rBPGlEPTB;Nz63Olc4OSEQvF2=	MYHTRW5ITVJ?
SW900	NVfncoVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTdwOEKxNlEh\|ryP	NVGzb4EzW0GQR1XS
JVM-3	NU\DR4tJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTdwOEm1PVkh\|ryP	NY\aUJI5W0GQR1XS
OAW-28	M3\0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfwVHNKSzVyPUeuPVQ2PzhizszN	NFHPeWdUSU6JRWK=
KURAMOCHI	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfFTWM2OD15Lkm0PFEyKM7:TR?=	NIO2[49USU6JRWK=
BE-13	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTdwOUixNVIh\|ryP	NUfKRlZ6W0GQR1XS
VMRC-RCZ	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfFTnByUUN3ME24MlAyPjl5IN88US=>	M37Xb3NCVkeHUh?=
NCI-H727	M4jadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETzd4lKSzVyPUiuNVA1OiEQvF2=	MVfTRW5ITVJ?
SW1710	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHCTWM2OD16LkG4OVE2KM7:TR?=	Ml[0V2FPT0WU
D-502MG	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S2ZmlEPTB;OD6yPVI5OiEQvF2=	NHfvb\|dUSU6JRWK=
NCI-H1993	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXWe3p3UUN3ME24MlM{PjNzIN88US=>	MVHTRW5ITVJ?
SCC-4	NWrsRYF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPZTWM2OD16LkS0NFU6KM7:TR?=	Mo\QV2FPT0WU
HAL-01	NUT3XnY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRThwNUG5NUDPxE1?	NFLhR5NUSU6JRWK=
GT3TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\0V2lEPTB;OD62O\|k3PCEQvF2=	NHXrTIxUSU6JRWK=
SK-OV-3	NH7NR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfUPFhKSzVyPUiuO\|E{OjlizszN	MV7TRW5ITVJ?
COLO-829	M2\6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;IbmtOUUN3ME24MlgxQTd4IN88US=>	MXvTRW5ITVJ?
OCI-AML2	MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPkeJV{UUN3ME24Mlk2PDhzIN88US=>	NXTre3l5W0GQR1XS
OS-RC-2	NXn5SYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfscXpzUUN3ME25MlAzOTlizszN	MWDTRW5ITVJ?
BFTC-909	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTlwME[3PVkh\|ryP	NUDmfWs{W0GQR1XS
EW-11	NGrEcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILjelBKSzVyPUmuNVc3PTNizszN	Mo\iV2FPT0WU
HCE-4	M2PuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTlwMkG1OVgh\|ryP	MoT1V2FPT0WU
BALL-1	NITsRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPhTWM2OD17LkKxPVA4KM7:TR?=	M3PzVnNCVkeHUh?=
SF539	NXHMN3U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzRTWM2OD17LkKzOVYzKM7:TR?=	M4\W[XNCVkeHUh?=
CAMA-1	MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkf6TWM2OD17LkK4NVI5KM7:TR?=	MXXTRW5ITVJ?
C32	NX3wN4dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTlwM{OwOlQh\|ryP	MY\TRW5ITVJ?
NCI-H1703	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzBbXRKSzVyPUmuN\|Q{PzVizszN	MXTTRW5ITVJ?
NCI-H1650	NE[1NlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPBbWdKSzVyPUmuOlA6PDZizszN	M1rnbXNCVkeHUh?=
NCI-H1563	M2\OSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y0S2lEPTB;OT63OlA{OSEQvF2=	NGm2TZdUSU6JRWK=
CAL-85-1	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\Yd3FGUUN3ME25Mlg4Ozh\|IN88US=>	M1fncnNCVkeHUh?=
UM-UC-3	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\DOIVKSzVyPUmuPVUxOyEQvF2=	NYX2NZhLW0GQR1XS
BxPC-3	NFHkblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLJTWM2OD1zMD6wPVczKM7:TR?=	MVzTRW5ITVJ?
MHH-PREB-1	NUfvOmtoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXPTWM2OD1zMD6xPVk6KM7:TR?=	MVvTRW5ITVJ?
DEL	MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjYTWM2OD1zMD6zPVQ3KM7:TR?=	NF7DSZhUSU6JRWK=
HuCCT1	NVHNOnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjQSFJ[UUN3ME2xNE43ODN\|IN88US=>	M3vYR3NCVkeHUh?=
OVCAR-4	NV7tU25HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELFSnRKSzVyPUGwMlg5OzVizszN	MYTTRW5ITVJ?
CAL-72	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPyTWM2OD1zMD65N\|kyKM7:TR?=	M3;Le3NCVkeHUh?=
HCC1954	M4XJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT4bow2UUN3ME2xNU4xPzV2IN88US=>	MX3TRW5ITVJ?
EFO-21	NFO5TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i1[GlEPTB;MUGuNVA1PSEQvF2=	M2\DUnNCVkeHUh?=
FTC-133	NYnNRndWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTFzLkG0NFch\|ryP	NGq5UXhUSU6JRWK=
SK-MEL-24	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFzLkKzOlYh\|ryP	M{\4RnNCVkeHUh?=
UACC-62	NXn4TFdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PXOmlEPTB;MUGuNlM3QCEQvF2=	NVP6[\|lyW0GQR1XS
NCI-H650	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTKTWM2OD1zMT6yOFE5KM7:TR?=	Ml3qV2FPT0WU
ALL-PO	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTFzLkK1NVIh\|ryP	MmHRV2FPT0WU
T84	M4PKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFzLkO5NFch\|ryP	M1HGV3NCVkeHUh?=
IST-MEL1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTFzLkS1OVkh\|ryP	Mk\1V2FPT0WU
SW626	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4Dw[WlEPTB;MUGuOVc2PSEQvF2=	MlHrV2FPT0WU
RPMI-2650	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnwXpZKSzVyPUGxMlU5QDVizszN	NWKzUoh{W0GQR1XS
MC-IXC	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\NcWlEPTB;MUGuOlczQCEQvF2=	NWP3UVhjW0GQR1XS
HOP-62	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzM[oh6UUN3ME2xNU43PzZ2IN88US=>	NXfSSFB7W0GQR1XS
NOS-1	NYfJelFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknwTWM2OD1zMT63NVA6KM7:TR?=	NIrDOXZUSU6JRWK=
SW1573	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTFzLkeyPVUh\|ryP	MWLTRW5ITVJ?
WM-115	NGXRR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDTb25HUUN3ME2xNU44PTh6IN88US=>	M2nKVnNCVkeHUh?=
HuO9	NF;Q[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTFzLki3O\|Qh\|ryP	M4Tv[HNCVkeHUh?=
YAPC	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XXbGlEPTB;MUGuPVI2QSEQvF2=	M4LZSnNCVkeHUh?=
MDA-MB-453	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHKb3Q4UUN3ME2xNU46PTF3IN88US=>	MVHTRW5ITVJ?
NCI-H596	NF\Cd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGX4NWRKSzVyPUGyMlA{PjlizszN	NELNbmVUSU6JRWK=
A172	M2q4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2CwW2lEPTB;MUKuNFc6QCEQvF2=	M3v4SnNCVkeHUh?=
RS4-11	NF;nfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPYTWM2OD1zMj6xO\|I2KM7:TR?=	NGrxOXVUSU6JRWK=
HCC1937	NFnyOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjGV2tKSzVyPUGyMlc2PjRizszN	M1rycHNCVkeHUh?=
SW837	M1LlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTF{LkmwNlgh\|ryP	NFLNeVdUSU6JRWK=
NMC-G1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmT0TWM2OD1zMj65NlM1KM7:TR?=	NILCbYpUSU6JRWK=
PFSK-1	NF36dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfkNZJKSzVyPUGzMlA3KM7:TR?=	NGj5Z4RUSU6JRWK=
DBTRG-05MG	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7Sb2NHUUN3ME2xN{4xPjN{IN88US=>	NV;jOmlzW0GQR1XS
SK-UT-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTF\|LkGwPFMh\|ryP	NXr3[FhZW0GQR1XS
OVCAR-5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnj[5RyUUN3ME2xN{4yPTl\|IN88US=>	Mkf6V2FPT0WU
8505C	NFnmNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTF\|LkKwOlch\|ryP	MkDSV2FPT0WU
SK-MEL-1	NWLHeXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLKTWM2OD1zMz63NVM2KM7:TR?=	M{fycXNCVkeHUh?=
LK-2	M2Do[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTF\|Lke2N\|kh\|ryP	NIntdVVUSU6JRWK=
OE33	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTF\|Lke4OkDPxE1?	MkHEV2FPT0WU
Ramos-2G6-4C10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K5b2lEPTB;MUSuNFIxOiEQvF2=	MnzVV2FPT0WU
EW-13	M{jTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTF2LkCzOVIh\|ryP	MXvTRW5ITVJ?
NCI-H1793	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXSbXB7UUN3ME2xOE4zODh5IN88US=>	NV65RnV5W0GQR1XS
BHT-101	M2fHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF2LkK0NUDPxE1?	MUfTRW5ITVJ?
RKO	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjXW4lKSzVyPUG0MlUxPzVizszN	M{WwcnNCVkeHUh?=
NEC8	NFn6VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIqzVGFKSzVyPUG0MlU1PzJizszN	MV\TRW5ITVJ?
PANC-10-05	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF2Lk[yOFch\|ryP	NUOyNVJCW0GQR1XS
NCI-H2030	NHvNSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHSTWM2OD1zND62OFQ5KM7:TR?=	MYTTRW5ITVJ?
C2BBe1	M3nkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjre\|RKSzVyPUG0Mlc3PCEQvF2=	NYHVTG1pW0GQR1XS
EM-2	NHzQZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\oOGlEPTB;MUSuPFU4PiEQvF2=	M{S0dXNCVkeHUh?=
HCC1395	M4roRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HhOmlEPTB;MUSuPVM{QCEQvF2=	MYnTRW5ITVJ?
A2058	NF3k[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnGyTWM2OD1zNT6wOFA6KM7:TR?=	MVjTRW5ITVJ?
SW1463	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHLfIZQUUN3ME2xOU4xPDh3IN88US=>	NULIe5ZIW0GQR1XS
J82	NHHQWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G1SmlEPTB;MUWuNFU4KM7:TR?=	MonpV2FPT0WU
CAL-120	M1TOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXteFZRUUN3ME2xOU4yPDR5IN88US=>	M1LldXNCVkeHUh?=
COLO-824	NV7SU3htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF:1eVBKSzVyPUG1MlE2PzlizszN	M4jpV3NCVkeHUh?=
LNCaP-Clone-FGC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLRTWM2OD1zNT60NlQ5KM7:TR?=	NIWzW\|lUSU6JRWK=
CP66-MEL	NIfXdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLZVotKSzVyPUG1MlQ3QDhizszN	MnH1V2FPT0WU
OC-314	M3;HXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4D3TGlEPTB;MUWuOFcyPCEQvF2=	NUPWcnhuW0GQR1XS
OVCAR-8	M1;ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[4PG5KSzVyPUG1Mlg5PjFizszN	MXTTRW5ITVJ?
MFE-280	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrMTWM2OD1zNj6wOFg5KM7:TR?=	NIXuOYNUSU6JRWK=
MHH-NB-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTF4LkC4N\|kh\|ryP	NH7EbZBUSU6JRWK=
SW1990	NXq5VIhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O4eGlEPTB;MU[uNVc2PSEQvF2=	Mle3V2FPT0WU
U-266	M{frXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3QeGFKSzVyPUG2MlIzQTlizszN	MUHTRW5ITVJ?
MFM-223	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTF4LkO5OlUh\|ryP	NXXFR5JUW0GQR1XS
L-363	M4rsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fsXGlEPTB;MU[uOFU4PyEQvF2=	NHzQXIZUSU6JRWK=
MCF7	NX\5R2xbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LOcWlEPTB;MU[uOFczOyEQvF2=	MXPTRW5ITVJ?
SK-MEL-3	M1TocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTF4LkS3PFch\|ryP	MWfTRW5ITVJ?
HH	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\NTWM2OD1zNj61NVYzKM7:TR?=	M4XnPXNCVkeHUh?=
no-10	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTF4Lk[zOFMh\|ryP	M{PEN3NCVkeHUh?=
HuP-T3	M3\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LwOmlEPTB;MU[uOlU4PiEQvF2=	MVjTRW5ITVJ?
QIMR-WIL	M4q5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfXTWM2OD1zNj63NVA2KM7:TR?=	NWLYNWlNW0GQR1XS
NCI-H1092	NWXSTGRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzEeJdKSzVyPUG2Mlg{OTZizszN	MlTYV2FPT0WU
MZ2-MEL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYX4WWdtUUN3ME2xOk45PDB\|IN88US=>	MXPTRW5ITVJ?
ES3	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HLZWlEPTB;MU[uPVE{PCEQvF2=	NYPubWhiW0GQR1XS
COLO-684	M4W0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlP4TWM2OD1zNj65OFc4KM7:TR?=	Mk\JV2FPT0WU
NCI-H661	MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPETWM2OD1zNj65Olk1KM7:TR?=	NGTuZlRUSU6JRWK=
CP50-MEL-B	NEHhUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTF5LkCzOFMh\|ryP	MXnTRW5ITVJ?
NCI-H2405	MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\WTWlEPTB;MUeuNVk4PCEQvF2=	MXPTRW5ITVJ?
U-2-OS	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTF5LkWzNFch\|ryP	NHvGRZZUSU6JRWK=
RERF-LC-MS	NGD4SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETXUnZKSzVyPUG3MlU2ODhizszN	MoDtV2FPT0WU
NCI-H2342	NIHkWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTF5LkW1O{DPxE1?	NHK2PHZUSU6JRWK=
ES8	NX3WNVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nNO2lEPTB;MUeuOlA5PyEQvF2=	MnzNV2FPT0WU
MOLT-16	NWTBW5B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTF5Lki5N\|Qh\|ryP	NIK5TZdUSU6JRWK=
RH-18	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zYeWlEPTB;MUiuNFA{PSEQvF2=	MWnTRW5ITVJ?
D-283MED	M{[yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULX[GsyUUN3ME2xPE4xODh6IN88US=>	MYPTRW5ITVJ?
RCC10RGB	M3e4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjYTHFVUUN3ME2xPE4xPTV7IN88US=>	M1nJU3NCVkeHUh?=
NCI-H1437	NIHITnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTF6LkG2OFEh\|ryP	NF61dHJUSU6JRWK=
SW982	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfPTGxDUUN3ME2xPE4zPjdzIN88US=>	NV7hT2FMW0GQR1XS
IST-MES1	NVnkV5NmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\tcmxVUUN3ME2xPE41PDJ6IN88US=>	MUDTRW5ITVJ?
A704	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;wTWM2OD1zOD60O\|U{KM7:TR?=	MkDJV2FPT0WU
ESS-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\ObVk5UUN3ME2xPE42OjB3IN88US=>	NGC1ZYVUSU6JRWK=
SCH	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTF6Lk[0OVYh\|ryP	MU\TRW5ITVJ?
COLO-320-HSR	NUTabZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjsTWM2OD1zOD63OFYh\|ryP	NYDXTpV5W0GQR1XS
Mo-T	NUfkdY1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO5TFdKSzVyPUG4MlgzODRizszN	NHja[FNUSU6JRWK=
Saos-2	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;HfZNKSzVyPUG5MlEyPjJizszN	Mn\1V2FPT0WU
SW684	NXroO\|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\2eplKSzVyPUG5MlE{OjZizszN	MXXTRW5ITVJ?
KMOE-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv4cZdKSzVyPUG5MlIzPDJizszN	NFXVToxUSU6JRWK=
MMAC-SF	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjFPHFKSzVyPUG5MlI3ODdizszN	NVPwPW9DW0GQR1XS
JAR	NV20cpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYO1e2pkUUN3ME2xPU4zQTlizszN	M1TEe3NCVkeHUh?=
SK-MEL-28	NXG0e\|dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDTZpRrUUN3ME2xPU4{OzZ\|IN88US=>	NVrTbo1wW0GQR1XS
KNS-81-FD	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjXVFZKSzVyPUG5MlU1PjhizszN	NGOzNWpUSU6JRWK=
ES7	M1WzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHi0SYtKSzVyPUG5MlYzQTJizszN	NVvZcHhmW0GQR1XS
AsPC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTF7Lk[0O\|Eh\|ryP	MX;TRW5ITVJ?
NCI-H1155	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXOfWhuUUN3ME2xPU44OjN6IN88US=>	MlT1V2FPT0WU
KYSE-510	NI\NSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF7Lki3OFgh\|ryP	NGDpWmtUSU6JRWK=
ES1	M3;3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTF7LkmyNVMh\|ryP	NVTlb5gyW0GQR1XS
PC-3	M1Lvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;BbJpKSzVyPUG5Mlk3ODRizszN	NWHuXGVmW0GQR1XS
GCT	M3ja[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[3NFVKSzVyPUKwMlMxOjZizszN	NH75PYJUSU6JRWK=
KARPAS-299	NE\1SXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTuWoY{UUN3ME2yNE4{PDJ{IN88US=>	NFGzfGtUSU6JRWK=
DOHH-2	M2jHNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnK4TWM2OD1{MD61OFY{KM7:TR?=	MoDsV2FPT0WU
COLO-741	M3fBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2f2Z2lEPTB;MkCuOlYh\|ryP	NWrnclBqW0GQR1XS
NCI-H1395	NGjqT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHnTWM2OD1{MD62Olk4KM7:TR?=	M3\qeXNCVkeHUh?=
HCC1187	M1\xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37q[2lEPTB;MkCuOlc{PCEQvF2=	NYHXbmFmW0GQR1XS
Becker	NXLHN\|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDQNnBKSzVyPUKwMlczODFizszN	MoXzV2FPT0WU
LU-134-A	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTJzLkGwNlYh\|ryP	NXuwXmtqW0GQR1XS
MKN45	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLQU2VDUUN3ME2yNU4yPTVzIN88US=>	NXPuVpVrW0GQR1XS
LC-2-ad	M3ru[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTJzLkK3Nlkh\|ryP	NHLEc4pUSU6JRWK=
EW-24	NVrQUXpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz3dpF[UUN3ME2yNU4{QTR3IN88US=>	M2SwcXNCVkeHUh?=
SK-N-AS	NH7IbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLWTWM2OD1{MT64Nlc3KM7:TR?=	MnnCV2FPT0WU
NCI-H2052	MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[yVmlEPTB;MkGuPFk3OyEQvF2=	NUnHd4pKW0GQR1XS
A4-Fuk	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TrUWlEPTB;MkKuNVQyQSEQvF2=	MUPTRW5ITVJ?
NB10	M4Oyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK4R5hKSzVyPUKyMlI{PzFizszN	MXrTRW5ITVJ?
CHP-212	NWDKcJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTJ{LkOyNlIh\|ryP	MnvHV2FPT0WU
KM12	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJ{LkO1OkDPxE1?	MkjiV2FPT0WU
JEG-3	NVzDW2hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTJ{LkO3PEDPxE1?	MkjvV2FPT0WU
LN-405	NX;kR2w1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXHfJA1UUN3ME2yNk42QTF\|IN88US=>	MX7TRW5ITVJ?
HCT-15	M3uwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzWNVhCUUN3ME2yNk44PDRzIN88US=>	MYLTRW5ITVJ?
MLMA	M17jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLGTWM2OD1{Mj63OFch\|ryP	NHnzR3JUSU6JRWK=
GI-1	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjIRXkxUUN3ME2yNk44PjV6IN88US=>	MnjSV2FPT0WU
RT-112	NWnDOVBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnu4TWM2OD1{Mj64OlE3KM7:TR?=	MVzTRW5ITVJ?
MPP-89	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPqd4dHUUN3ME2yNk45PjZzIN88US=>	MXXTRW5ITVJ?
A3-KAW	NYLQXIJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJ\|LkGwNFMh\|ryP	MXrTRW5ITVJ?
KALS-1	NGDXNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vacmlEPTB;MkOuNVQyPCEQvF2=	MYnTRW5ITVJ?
SF126	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJ\|Lk[5NlQh\|ryP	MmrDV2FPT0WU
SiHa	MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkW0TWM2OD1{Mz65N\|I4KM7:TR?=	MmjDV2FPT0WU
MDA-MB-415	NYDmdVBsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnwTWM2OD1{Mz65OFk6KM7:TR?=	NYjaV\|lKW0GQR1XS
Daoy	M3q4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[yOGlEPTB;MkSuNVI3KM7:TR?=	MVzTRW5ITVJ?
COR-L23	M1PUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnO5TWM2OD1{ND6xO\|Y4KM7:TR?=	NXXUZ3Z2W0GQR1XS
KG-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jKOWlEPTB;MkSuNVkzQCEQvF2=	NHTISnZUSU6JRWK=
L-428	Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj1dZFKSzVyPUK0MlU4QTFizszN	MXHTRW5ITVJ?
NCI-H520	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TET2lEPTB;MkSuPFg3OSEQvF2=	MlyyV2FPT0WU
COLO-792	M3r3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF76U4RKSzVyPUK1MlI4OzJizszN	NHPnN4ZUSU6JRWK=
NB12	NXT1dI9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX4OJcxUUN3ME2yOU4zQTR5IN88US=>	MnraV2FPT0WU
GAK	NETBU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHqzT4VKSzVyPUK1MlI6PjNizszN	M2LE[XNCVkeHUh?=
SW780	NIrES3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\afZVKSzVyPUK1MlMzPjRizszN	MnzsV2FPT0WU
GB-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nMeWlEPTB;MkWuOFA3QSEQvF2=	Mk[1V2FPT0WU
P12-ICHIKAWA	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLLXFkxUUN3ME2yOU41Pzh3IN88US=>	NV[5eWpNW0GQR1XS
NCI-H1651	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\COYhUUUN3ME2yOU42QTdizszN	NH;vV2dUSU6JRWK=
KE-37	M3fj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXn6d2J7UUN3ME2yOU44OzF3IN88US=>	MXHTRW5ITVJ?
CCRF-CEM	NGXD[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2L4b2lEPTB;MkWuPVY4KM7:TR?=	M2ezWHNCVkeHUh?=
SF295	NW\ENVlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jITWlEPTB;Mk[uNFQzPSEQvF2=	M1L1fnNCVkeHUh?=
G-361	NFrXSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;UTWM2OD1{Nj6xNFI4KM7:TR?=	MXXTRW5ITVJ?
HOP-92	M17wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTJ4LkGyNlYh\|ryP	M4S2eXNCVkeHUh?=
UMC-11	M3nncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfHTWM2OD1{Nj60OVE1KM7:TR?=	MlL2V2FPT0WU
IST-SL1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfvc4FKSzVyPUK2MlY2QTFizszN	NXnPPGNCW0GQR1XS
TE-11	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\NOmlEPTB;Mk[uO\|c2OiEQvF2=	MoXUV2FPT0WU
NCI-H1304	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLMTWM2OD1{Nj65NVA5KM7:TR?=	NETHWYRUSU6JRWK=
SJSA-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTJ5LkCxO\|Yh\|ryP	MoLXV2FPT0WU
BCPAP	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\2e2lEPTB;MkeuNVM4KM7:TR?=	M1nDXnNCVkeHUh?=
HTC-C3	NGG0dYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjH[257UUN3ME2yO{4zPTZzIN88US=>	NVHPXmxZW0GQR1XS
EW-16	NYLXUnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1mwTmlEPTB;MkeuNlk1PyEQvF2=	NWjKNWVUW0GQR1XS
HT-144	NWfj[4V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHTephKSzVyPUK3MlQxOzJizszN	NE\TR2lUSU6JRWK=
MHH-ES-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\rbGlEPTB;MkeuOFQ1PyEQvF2=	NXW4dmExW0GQR1XS
T98G	NF[0W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4K1WWlEPTB;MkeuOVg1PiEQvF2=	M2fKe3NCVkeHUh?=
RPMI-8866	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUKxbZpiUUN3ME2yO{44PTZ{IN88US=>	MVXTRW5ITVJ?
BEN	NED2cJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETNZZJKSzVyPUK3Mlg2OTdizszN	NHjacm9USU6JRWK=
MDA-MB-231	NFrUWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXL6WVN[UUN3ME2yPE4zPzl3IN88US=>	MVzTRW5ITVJ?
HuH-7	NVHVc5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTJTWM2OD1{OD60NFI5KM7:TR?=	MVXTRW5ITVJ?
SK-N-FI	NETocpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPmcY9KSzVyPUK4MlQ{OyEQvF2=	NXjnW4ZoW0GQR1XS
AN3-CA	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\Sb2lEPTB;MkiuOFM6PSEQvF2=	MoizV2FPT0WU
EGI-1	NEHHZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfMTWM2OD1{OD61PVI5KM7:TR?=	M3P0S3NCVkeHUh?=
697	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTmU4JKSzVyPUK4MlY{OzFizszN	Mnq5V2FPT0WU
TCCSUP	NGDRTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXRb\|BuUUN3ME2yPE43PDF6IN88US=>	NHzuUVZUSU6JRWK=
GR-ST	NYH5e\|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWqydHJCUUN3ME2yPE43Pjl4IN88US=>	NFHRZpFUSU6JRWK=
SK-N-DZ	NYXzNVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTqblVqUUN3ME2yPE43QDh3IN88US=>	NFS1bXZUSU6JRWK=
MIA-PaCa-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;idI1LUUN3ME2yPE44QTV7IN88US=>	NHTxVVJUSU6JRWK=
IGR-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f0SWlEPTB;MkiuPFg4PCEQvF2=	MV\TRW5ITVJ?
BFTC-905	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPuTWM2OD1{OT6yO\|A2KM7:TR?=	MkPDV2FPT0WU
NCI-H1581	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C1OGlEPTB;MkmuN\|E1PSEQvF2=	MmPoV2FPT0WU
RD	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTJ7LkWyN\|Mh\|ryP	NHrFSYRUSU6JRWK=
SF268	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7OSFFKSzVyPUK5MlU6OzFizszN	MW\TRW5ITVJ?
SHP-77	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLjfXplUUN3ME2yPU43OTh{IN88US=>	NGL4OFJUSU6JRWK=
D-566MG	M4jJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1OwbmlEPTB;MkmuPVM6OyEQvF2=	M2TheXNCVkeHUh?=
TGBC1TKB	NHL5UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHaZ5ZCUUN3ME2zNE4yOjN6IN88US=>	M4rNO3NCVkeHUh?=
MEL-HO	NH70Vo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljmTWM2OD1\|MD6xOFI{KM7:TR?=	MWXTRW5ITVJ?
SJRH30	M3[5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nVPWlEPTB;M{CuNlExQCEQvF2=	NHHz[\|ZUSU6JRWK=
D-336MG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTNyLkK4PVIh\|ryP	M174VXNCVkeHUh?=
C3A	NH\VU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDjZlhKSzVyPUOwMlI6OjdizszN	MYTTRW5ITVJ?
Calu-6	NF3KOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7CcIRKSzVyPUOwMlI6PjNizszN	Ml70V2FPT0WU
MZ1-PC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jDdGlEPTB;M{CuN\|k{KM7:TR?=	NXexeYNsW0GQR1XS
KYSE-70	NX[5UFNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\pd5dKSzVyPUOwMlUyOTRizszN	MVnTRW5ITVJ?
CAPAN-1	NHG2XWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fUT2lEPTB;M{CuOVE5OSEQvF2=	MXrTRW5ITVJ?
DK-MG	NEHn[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\wcGtKSzVyPUOwMlU1PTZizszN	MYPTRW5ITVJ?
SK-HEP-1	M3nxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTNyLk[zNlYh\|ryP	Ml3iV2FPT0WU
MS-1	NWfVSpl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzmTWM2OD1\|MD64PFg6KM7:TR?=	NXjvWldwW0GQR1XS
GI-ME-N	M1\USmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLsTWM2OD1\|MT6wOVcyKM7:TR?=	NHixUlBUSU6JRWK=
NCI-H510A	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\QTWM2OD1\|MT60NFA3KM7:TR?=	MVHTRW5ITVJ?
NB17	M2XlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfVSZZKSzVyPUOxMlUyQDVizszN	M3[5UHNCVkeHUh?=
639-V	NWDpNIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXxTWM2OD1\|MT61NlQ{KM7:TR?=	NEK0XVhUSU6JRWK=
CAL-51	NYmyem5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTNzLkW2Olch\|ryP	MkHVV2FPT0WU
HGC-27	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTNzLkW4O\|Mh\|ryP	M1vMT3NCVkeHUh?=
GOTO	NWPyTol4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITzS5FKSzVyPUOxMlg2ODZizszN	MoOwV2FPT0WU
ChaGo-K-1	M13CPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDMTWM2OD1\|Mj6wNFch\|ryP	NGTpc\|RUSU6JRWK=
RO82-W-1	NGPi[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTN{LkG2NFQh\|ryP	NVPyNZJiW0GQR1XS
SH-4	M2PQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTN{LkG4OVgh\|ryP	MnHVV2FPT0WU
A204	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPjTWM2OD1\|Mj61NFY6KM7:TR?=	MXXTRW5ITVJ?
DMS-273	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nlZWlEPTB;M{KuOVMzOiEQvF2=	M3\X[HNCVkeHUh?=
KGN	M3fVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fUWGlEPTB;M{KuOlM{KM7:TR?=	NFLvfJpUSU6JRWK=
SK-MEL-2	NYnaPGQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHpTWM2OD1\|Mj62OVI4KM7:TR?=	NV\YUXVWW0GQR1XS
NCI-H2228	M2n4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTN{Lk[2NFIh\|ryP	M2HDb3NCVkeHUh?=
MKN28	NF3vSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXuwboZOUUN3ME2zNk44QDN6IN88US=>	NF\C[2lUSU6JRWK=
H-EMC-SS	NXP1d\|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLWTWM2OD1\|Mj65Olc5KM7:TR?=	MVHTRW5ITVJ?
ATN-1	NGnmfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2T3eGlEPTB;M{OuNVQyPiEQvF2=	NF[0UoJUSU6JRWK=
D-263MG	NHv2TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjrW5dKSzVyPUOzMlg{PzhizszN	M33YWHNCVkeHUh?=
LU-135	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPDTWM2OD1\|Mz64PFI6KM7:TR?=	NHfFdXFUSU6JRWK=
C8166	NEDTSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofkTWM2OD1\|Mz64PFU1KM7:TR?=	NIPqOGJUSU6JRWK=
T-24	M2rJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHDTWM2OD1\|ND6wNlA2KM7:TR?=	NILzfmNUSU6JRWK=
Mewo	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTN2LkGzOFkh\|ryP	Mlu2V2FPT0WU
22RV1	NUX6bXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HOd2lEPTB;M{SuNVc2PCEQvF2=	MmTXV2FPT0WU
KM-H2	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTN2LkG3O\|kh\|ryP	M3LYRnNCVkeHUh?=
NCI-H2122	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M125PWlEPTB;M{SuN\|Q4OSEQvF2=	Ml7GV2FPT0WU
ABC-1	M2[3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDKb3pKSzVyPUO0MlM3QTNizszN	MkDpV2FPT0WU
NCI-H1355	NWnZeoc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFOxO4VKSzVyPUO0MlM5QDlizszN	MWTTRW5ITVJ?
NOMO-1	NVW4dWdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;xSpRKSzVyPUO0MlU4ODNizszN	NH\kZllUSU6JRWK=
MZ7-mel	NVLUV4Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXWTWM2OD1\|ND62OFg4KM7:TR?=	M2\KUHNCVkeHUh?=
NCI-H810	Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTN2LkeyO\|gh\|ryP	NXnSRoJyW0GQR1XS
D-392MG	NYTZdmFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfrS3lKSzVyPUO1MlA2PjVizszN	NU\SUXBtW0GQR1XS
LB771-HNC	NYOyNppwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTN3LkG2OVgh\|ryP	MnrTV2FPT0WU
COLO-679	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfhbXoyUUN3ME2zOU4{QDhizszN	MlHHV2FPT0WU
SK-PN-DW	M2XoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTaWHluUUN3ME2zOU41OzZ7IN88US=>	MYPTRW5ITVJ?
VA-ES-BJ	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTN3LkS2OFkh\|ryP	Mmr4V2FPT0WU
KNS-42	M1P3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPBTWM2OD1\|NT61PFI3KM7:TR?=	NF:0R25USU6JRWK=
RVH-421	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvrTWM2OD1\|NT63OlQ2KM7:TR?=	NH;YS\|JUSU6JRWK=
P30-OHK	NXvmZW9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\Sd2lEPTB;M{WuPFc2OiEQvF2=	MnPlV2FPT0WU
G-402	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPrTWM2OD1\|NT65PFY4KM7:TR?=	MVjTRW5ITVJ?
S-117	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7mWmpKSzVyPUO2MlMxODhizszN	MWTTRW5ITVJ?
RXF393	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTN4LkO3PFUh\|ryP	NGjOUmNUSU6JRWK=
LCLC-103H	NVX1W\|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfu[m5tUUN3ME2zOk44QDB\|IN88US=>	NXfGcGVGW0GQR1XS
U-118-MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTN4Lki4OFch\|ryP	NV23OZF7W0GQR1XS
8-MG-BA	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;UR2lEPTB;M{[uPVQ5OyEQvF2=	MkHxV2FPT0WU
MFH-ino	NWHzOJdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{e0[2lEPTB;M{euN\|M4OSEQvF2=	MXzTRW5ITVJ?
NCI-H23	M4H3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDxXW4zUUN3ME2zO{41OTl4IN88US=>	MWfTRW5ITVJ?
NCI-H446	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7yTWM2OD1\|Nz60PFYzKM7:TR?=	NGewVVlUSU6JRWK=
LU-99A	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjLRZBKSzVyPUO3MlU4OzFizszN	M{Xyb3NCVkeHUh?=
KP-N-YN	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTN5Lk[xPVUh\|ryP	MV\TRW5ITVJ?
SCC-9	NXPFOGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jqZmlEPTB;M{euO\|g{QCEQvF2=	NEHLcZdUSU6JRWK=
EFM-19	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTN5Lke5Olch\|ryP	MnS2V2FPT0WU
A427	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HMbGlEPTB;M{euPVExPyEQvF2=	M4D3[XNCVkeHUh?=
LB831-BLC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTN6Lk[wN\|kh\|ryP	MmfRV2FPT0WU
HOS	NGm5SVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPXbllKSzVyPUO5MlYzPzNizszN	NFvkeWlUSU6JRWK=
LAN-6	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHYboFKSzVyPUSwMlAyOTJizszN	M130VXNCVkeHUh?=
U251	NXn0dlA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnWzTWM2OD12MD60NFU1KM7:TR?=	MYXTRW5ITVJ?
SNU-387	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTRyLkS1OVMh\|ryP	MVrTRW5ITVJ?
DMS-79	NHH1fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEX4c49KSzVyPUSwMlU5QDlizszN	Ml:wV2FPT0WU
SK-LU-1	M2D1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTKTWM2OD12MD62OVY5KM7:TR?=	NX;6dFR6W0GQR1XS
HT	NUSwdJYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTRyLk[2N\|kh\|ryP	MlrSV2FPT0WU
KP-N-YS	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTRyLk[3Olgh\|ryP	NIHOTnhUSU6JRWK=
DMS-114	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XieGlEPTB;NECuPFM4PCEQvF2=	NG[xPFlUSU6JRWK=
HUTU-80	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3K5XGlEPTB;NEGuNFU3QSEQvF2=	NHG2SZdUSU6JRWK=
ONS-76	NVOzd3JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWraVFRbUUN3ME20NU41PzB7IN88US=>	NIPKNolUSU6JRWK=
A673	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjWOZFKUUN3ME20NU42OTV5IN88US=>	MWLTRW5ITVJ?
HPAF-II	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LaTmlEPTB;NEGuOlcxQSEQvF2=	Ml3pV2FPT0WU
UACC-257	NXrlepNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fOXWlEPTB;NEGuO\|M3QSEQvF2=	M1zqenNCVkeHUh?=
EW-22	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn:xTWM2OD12MT64Olk4KM7:TR?=	NGXD[YpUSU6JRWK=
NCI-H1755	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTRzLki3NlUh\|ryP	NE\SXJNUSU6JRWK=
KYSE-150	NGrrN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\WTWM2OD12Mj6xO\|gzKM7:TR?=	NYLZOHFXW0GQR1XS
CGTH-W-1	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfod\|lEUUN3ME20Nk41QTV3IN88US=>	M1LZSXNCVkeHUh?=
NB13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3YWHRKSzVyPUSyMlYzOTdizszN	Mnu3V2FPT0WU
SW872	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTR{Lk[zN\|Eh\|ryP	NYHTdlF1W0GQR1XS
KP-4	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zjbWlEPTB;NEKuPFg{OiEQvF2=	MV7TRW5ITVJ?
HCC38	M{\WWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTR{Lkm2NVgh\|ryP	NYHpeVJbW0GQR1XS
BB49-HNC	M4fZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS5T3dKSzVyPUSzMlI{PTZizszN	M3job3NCVkeHUh?=
CAL-62	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\qXWJKSzVyPUSzMlQxOjhizszN	NFPZVHpUSU6JRWK=
NCI-H2029	NFy2epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTR\|LkW1PFEh\|ryP	MVXTRW5ITVJ?
M14	NUTtbplkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\ucGlEPTB;NESuNVM{OiEQvF2=	NFH1VYRUSU6JRWK=
COLO-680N	M4r5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkm5TWM2OD12ND6zN\|kh\|ryP	MniwV2FPT0WU
Hs-578-T	NWW1T45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfJVGFKSzVyPUS1MlAzQTRizszN	NEjsfVRUSU6JRWK=
MSTO-211H	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{GyRmlEPTB;NEWuPVQ5OiEQvF2=	MVHTRW5ITVJ?
EW-1	NW\H[IlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTR3Lkm2PFkh\|ryP	MUTTRW5ITVJ?
SW948	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjrTWM2OD12Nj60OFYzKM7:TR?=	Mn7TV2FPT0WU
NCI-H460	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2C0OWlEPTB;NE[uOVI{KM7:TR?=	M3G0e3NCVkeHUh?=
CAS-1	NUPyc\|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPGTWM2OD12Nj63O\|AyKM7:TR?=	NH3kXFBUSU6JRWK=
TGBC11TKB	NYLnd3JTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXMT3RKSzVyPUS3MlE4PzdizszN	MWnTRW5ITVJ?
HD-MY-Z	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rSR2lEPTB;NEiuO\|g3KM7:TR?=	M4HsTnNCVkeHUh?=
NCI-H226	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPUTWM2OD12OT63O\|g2KM7:TR?=	MW\TRW5ITVJ?
PA-1	Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jENmlEPTB;NEmuPFM{PSEQvF2=	Mlz4V2FPT0WU
LB2518-MEL	NUXTO5ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvpTWM2OD12OT64O\|I{KM7:TR?=	NILXdYJUSU6JRWK=
A101D	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3RV5lKSzVyPUS5Mlk1OjVizszN	MYfTRW5ITVJ?
NCI-H2087	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT1b\|V7UUN3ME20PU46Pjh{IN88US=>	M4SzbnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Water	Insoluble
	Ethanol	''15 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	850140-72-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)C/C=C/C(=O)NC1=CC2=C(NC3=CC=C(F)C(=C3)Cl)N=CN=C2C=C1OC4CCOC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04206787	Not yet recruiting	Drug: Afatinib	Non-squamous Non-Small Cell Lung Cancer	Boehringer Ingelheim	May 6 2020	--
NCT04158947	Recruiting	Drug: Afatinib\|Drug: T-DM1	HER2-positive Breast Cancer\|Brain Metastases	xuexin he\|Second Affiliated Hospital School of Medicine Zhejiang University	May 10 2020	Phase 2
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2
NCT03370770	Completed	Drug: Afatinib\|Drug: Osimertinib	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	December 28 2017	--
NCT02423525	Recruiting	Drug: Afatinib	Brain Cancer	Santosh Kesari\|Boehringer Ingelheim\|John Wayne Cancer Institute	December 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)